Drug:
Reaction: OFF LABEL USE
20260101 - 20261231
No. 101 - 200
| No. | safetyreportid |
occurcountry |
patientonsetage |
patientsex 1:M 2:F |
|---|---|---|---|---|
Adverse reaction |
||||
Drug (openfda.generic_name, medicinalproduct) |
||||
| 101 | 26556138 |
US |
||
Drug ineffective, Off label use, |
||||
PRABOTULINUM TOXIN TYPE A, PRABOTULINUM TOXIN TYPE A, |
||||
| 102 | 26556140 |
US |
||
Drug ineffective for unapproved indication, Off label use, |
||||
PRABOTULINUM TOXIN TYPE A, PRABOTULINUM TOXIN TYPE A, PRABOTULINUM TOXIN TYPE A, |
||||
| 103 | 26556141 |
US |
57 | |
Feeling hot, Rash, Burning sensation, Off label use, |
||||
PRABOTULINUM TOXIN TYPE A, PRABOTULINUM TOXIN TYPE A, PRABOTULINUM TOXIN TYPE A, |
||||
| 104 | 26556142 |
US |
||
Drug effect less than expected, Off label use, |
||||
PRABOTULINUM TOXIN TYPE A, PRABOTULINUM TOXIN TYPE A, PRABOTULINUM TOXIN TYPE A, |
||||
| 105 | 26556143 |
US |
||
Drug ineffective, Off label use, |
||||
PRABOTULINUM TOXIN TYPE A, PRABOTULINUM TOXIN TYPE A, PRABOTULINUM TOXIN TYPE A, |
||||
| 106 | 26556144 |
US |
||
Drug ineffective, Off label use, |
||||
PRABOTULINUM TOXIN TYPE A, PRABOTULINUM TOXIN TYPE A, PRABOTULINUM TOXIN TYPE A, |
||||
| 107 | 26556145 |
US |
||
Drug ineffective for unapproved indication, Off label use, |
||||
PRABOTULINUM TOXIN TYPE A, |
||||
| 108 | 26556146 |
US |
69 | |
Cataract operation, Visual impairment, Vitreous floaters, Eczema, Off label use, |
||||
PRABOTULINUM TOXIN TYPE A, PRABOTULINUM TOXIN TYPE A, HYALURONIC ACID, |
||||
| 109 | 26556147 |
US |
||
Drug effect less than expected, Off label use, |
||||
PRABOTULINUM TOXIN TYPE A, PRABOTULINUM TOXIN TYPE A, PRABOTULINUM TOXIN TYPE A, |
||||
| 110 | 26556149 |
US |
||
Drug ineffective, Off label use, |
||||
PRABOTULINUM TOXIN TYPE A, PRABOTULINUM TOXIN TYPE A, |
||||
| 111 | 26556150 |
US |
||
Drug ineffective, Off label use, |
||||
PRABOTULINUM TOXIN TYPE A, PRABOTULINUM TOXIN TYPE A, PRABOTULINUM TOXIN TYPE A, |
||||
| 112 | 26556152 |
US |
||
Drug effect less than expected, Off label use, |
||||
PRABOTULINUM TOXIN TYPE A, |
||||
| 113 | 26556155 |
EU |
62 | |
Death, Ependymoma, Off label use, |
||||
BEVACIZUMAB, BEVACIZUMAB, TEMOZOLOMIDE, |
||||
| 114 | 26556158 |
US |
||
Drug ineffective, Off label use, |
||||
PRABOTULINUM TOXIN TYPE A, |
||||
| 115 | 26556159 |
US |
||
Drug effect less than expected, Drug ineffective, Off label use, |
||||
PRABOTULINUM TOXIN TYPE A, PRABOTULINUM TOXIN TYPE A, PRABOTULINUM TOXIN TYPE A, |
||||
| 116 | 26556160 |
US |
||
Oral herpes, Off label use, |
||||
PRABOTULINUM TOXIN TYPE A, |
||||
| 117 | 26556161 |
US |
38 | |
Petechiae, Off label use, |
||||
PRABOTULINUM TOXIN TYPE A, PRABOTULINUM TOXIN TYPE A, |
||||
| 118 | 26556163 |
US |
||
Drug ineffective for unapproved indication, Off label use, |
||||
PRABOTULINUM TOXIN TYPE A, |
||||
| 119 | 26556164 |
US |
57 | |
Discomfort, Eye contusion, Hypoaesthesia, Swelling, Vision blurred, Off label use, |
||||
PRABOTULINUM TOXIN TYPE A, PRABOTULINUM TOXIN TYPE A, PRABOTULINUM TOXIN TYPE A, |
||||
| 120 | 26556165 |
US |
||
Drug ineffective, Off label use, |
||||
PRABOTULINUM TOXIN TYPE A, |
||||
| 121 | 26556183 |
US |
||
Off label use, Product counterfeit, |
||||
ONABOTULINUMTOXINA, ONABOTULINUMTOXINA, |
||||
| 122 | 26556189 |
US |
||
Drug ineffective, Off label use, |
||||
PRABOTULINUM TOXIN TYPE A, PRABOTULINUM TOXIN TYPE A, PRABOTULINUM TOXIN TYPE A, |
||||
| 123 | 26556191 |
US |
||
Drug ineffective, Off label use, |
||||
PRABOTULINUM TOXIN TYPE A, PRABOTULINUM TOXIN TYPE A, PRABOTULINUM TOXIN TYPE A, |
||||
| 124 | 26556208 |
US |
36 | |
Asthenia, Dizziness, Vision blurred, Nausea, Pain, Brain fog, Malaise, Off label use, |
||||
PRABOTULINUM TOXIN TYPE A, PRABOTULINUM TOXIN TYPE A, |
||||
| 125 | 26556211 |
US |
||
Injection site swelling, Off label use, |
||||
PRABOTULINUM TOXIN TYPE A, PRABOTULINUM TOXIN TYPE A, PRABOTULINUM TOXIN TYPE A, |
||||
| 126 | 26556212 |
US |
||
Drug effect less than expected, Off label use, |
||||
PRABOTULINUM TOXIN TYPE A, |
||||
| 127 | 26556213 |
US |
||
Drug ineffective, Off label use, |
||||
PRABOTULINUM TOXIN TYPE A, PRABOTULINUM TOXIN TYPE A, |
||||
| 128 | 26556214 |
US |
62 | |
Drug ineffective, Drug effect less than expected, Off label use, |
||||
PRABOTULINUM TOXIN TYPE A, PRABOTULINUM TOXIN TYPE A, PRABOTULINUM TOXIN TYPE A, |
||||
| 129 | 26556215 |
US |
||
Drug ineffective, Off label use, |
||||
PRABOTULINUM TOXIN TYPE A, PRABOTULINUM TOXIN TYPE A, |
||||
| 130 | 26556217 |
US |
||
Drug ineffective, Off label use, |
||||
PRABOTULINUM TOXIN TYPE A, PRABOTULINUM TOXIN TYPE A, |
||||
| 131 | 26556243 |
US |
26 | |
Drug ineffective, Off label use, |
||||
PRABOTULINUM TOXIN TYPE A, |
||||
| 132 | 26556244 |
US |
24 | |
Drug ineffective, Off label use, |
||||
PRABOTULINUM TOXIN TYPE A, |
||||
| 133 | 26556245 |
US |
||
Drug ineffective, Off label use, |
||||
PRABOTULINUM TOXIN TYPE A, PRABOTULINUM TOXIN TYPE A, PRABOTULINUM TOXIN TYPE A, |
||||
| 134 | 26556248 |
US |
||
Drug effect less than expected, Off label use, |
||||
PRABOTULINUM TOXIN TYPE A, PRABOTULINUM TOXIN TYPE A, |
||||
| 135 | 26556277 |
US |
||
Off label use, |
||||
BICTEGRAVIR SODIUM, EMTRICITABINE, AND TENOFOVIR ALAFENAMIDE FUMARATE, |
||||
| 136 | 26556291 |
US |
57 | 2 |
Constipation, Off label use, Diarrhoea, |
||||
ABEMACICLIB, ABEMACICLIB, ABEMACICLIB, |
||||
| 137 | 26556304 |
US |
37 | |
Drug ineffective, Off label use, |
||||
PRABOTULINUM TOXIN TYPE A, |
||||
| 138 | 26556311 |
US |
||
Drug ineffective, Off label use, |
||||
PRABOTULINUM TOXIN TYPE A, |
||||
| 139 | 26556312 |
US |
55 | |
Injection site pruritus, Injection site urticaria, Injection site erythema, Off label use, |
||||
PRABOTULINUM TOXIN TYPE A, PRABOTULINUM TOXIN TYPE A, PRABOTULINUM TOXIN TYPE A, |
||||
| 140 | 26556331 |
US |
||
Injection site pain, Off label use, |
||||
PRABOTULINUM TOXIN TYPE A, |
||||
| 141 | 26556332 |
US |
||
Injection site mass, Off label use, |
||||
PRABOTULINUM TOXIN TYPE A, |
||||
| 142 | 26556334 |
US |
||
Swelling of eyelid, Erythema of eyelid, Off label use, |
||||
PRABOTULINUM TOXIN TYPE A, PRABOTULINUM TOXIN TYPE A, PRABOTULINUM TOXIN TYPE A, |
||||
| 143 | 26556337 |
US |
30 | |
Drug effect less than expected, Off label use, |
||||
PRABOTULINUM TOXIN TYPE A, PRABOTULINUM TOXIN TYPE A, PRABOTULINUM TOXIN TYPE A, |
||||
| 144 | 26556338 |
US |
||
Drug effect less than expected, Off label use, |
||||
PRABOTULINUM TOXIN TYPE A, PRABOTULINUM TOXIN TYPE A, |
||||
| 145 | 26556339 |
US |
47 | |
Drug ineffective, Off label use, |
||||
PRABOTULINUM TOXIN TYPE A, PRABOTULINUM TOXIN TYPE A, PRABOTULINUM TOXIN TYPE A, |
||||
| 146 | 26556340 |
US |
55 | |
Drug effect less than expected, Off label use, |
||||
PRABOTULINUM TOXIN TYPE A, PRABOTULINUM TOXIN TYPE A, PRABOTULINUM TOXIN TYPE A, |
||||
| 147 | 26556341 |
US |
43 | |
Drug effect less than expected, Off label use, |
||||
PRABOTULINUM TOXIN TYPE A, PRABOTULINUM TOXIN TYPE A, PRABOTULINUM TOXIN TYPE A, |
||||
| 148 | 26556344 |
US |
42 | |
Drug ineffective, Off label use, |
||||
PRABOTULINUM TOXIN TYPE A, PRABOTULINUM TOXIN TYPE A, PRABOTULINUM TOXIN TYPE A, |
||||
| 149 | 26556347 |
US |
30 | |
Headache, Paraesthesia, Burning sensation, Vision blurred, Hypoaesthesia, Urinary incontinence, Nausea, Dry mouth, Dysphagia, Off label use, |
||||
PRABOTULINUM TOXIN TYPE A, PRABOTULINUM TOXIN TYPE A, PRABOTULINUM TOXIN TYPE A, |
||||
| 150 | 26556353 |
US |
36 | |
Drug ineffective, Off label use, |
||||
PRABOTULINUM TOXIN TYPE A, |
||||
| 151 | 26556355 |
US |
||
Drug ineffective, Off label use, |
||||
PRABOTULINUM TOXIN TYPE A, PRABOTULINUM TOXIN TYPE A, PRABOTULINUM TOXIN TYPE A, |
||||
| 152 | 26556356 |
US |
||
Drug ineffective, Off label use, |
||||
PRABOTULINUM TOXIN TYPE A, PRABOTULINUM TOXIN TYPE A, |
||||
| 153 | 26556358 |
US |
||
Drug ineffective, Off label use, |
||||
PRABOTULINUM TOXIN TYPE A, PRABOTULINUM TOXIN TYPE A, PRABOTULINUM TOXIN TYPE A, |
||||
| 154 | 26556360 |
US |
59 | |
Drug ineffective, Off label use, |
||||
PRABOTULINUM TOXIN TYPE A, |
||||
| 155 | 26556361 |
US |
||
Drug ineffective, Off label use, |
||||
PRABOTULINUM TOXIN TYPE A, PRABOTULINUM TOXIN TYPE A, |
||||
| 156 | 26556369 |
US |
58 | |
Drug ineffective, Off label use, |
||||
PRABOTULINUM TOXIN TYPE A, PRABOTULINUM TOXIN TYPE A, PRABOTULINUM TOXIN TYPE A, |
||||
| 157 | 26556374 |
US |
||
Drug ineffective, Off label use, |
||||
PRABOTULINUM TOXIN TYPE A, PRABOTULINUM TOXIN TYPE A, |
||||
| 158 | 26556379 |
CA |
45 | |
Blood pressure increased, Weight decreased, Blood pressure diastolic increased, Heart rate increased, Salmonellosis, Weight increased, Myalgia, Arthralgia, Therapeutic response shortened, Off label use, Off label use, Intentional product use issue, Inappropriate schedule of product administration, Off label use, Intentional product use issue, |
||||
INFLIXIMAB, INFLIXIMAB, INFLIXIMAB, INFLIXIMAB, INFLIXIMAB, INFLIXIMAB, INFLIXIMAB, INFLIXIMAB, INFLIXIMAB, INFLIXIMAB, INFLIXIMAB, INFLIXIMAB, INFLIXIMAB, INFLIXIMAB, INFLIXIMAB, INFLIXIMAB, INFLIXIMAB, INFLIXIMAB, INFLIXIMAB, INFLIXIMAB, INFLIXIMAB, INFLIXIMAB, INFLIXIMAB, INFLIXIMAB, INFLIXIMAB, INFLIXIMAB, INFLIXIMAB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, |
||||
| 159 | 26556383 |
US |
56 | 1 |
Toxic anterior segment syndrome, Blindness, Pseudohypopyon, Vitrectomy, Corneal oedema, Medical device removal, Device dislocation, Off label use, |
||||
FLUOCINOLONE ACETONIDE, MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL HYDROCHLORIDE, |
||||
| 160 | 26556387 |
US |
42 | |
Anxiety, Panic attack, Muscular weakness, Abdominal pain, Heart rate increased, Dizziness, Brain fog, Muscle twitching, Muscle spasms, Hypoaesthesia, Off label use, |
||||
PRABOTULINUM TOXIN TYPE A, TIRZEPATIDE, |
||||
| 161 | 26556389 |
US |
||
Drug ineffective, Off label use, |
||||
PRABOTULINUM TOXIN TYPE A, |
||||
| 162 | 26556390 |
US |
51 | |
Fluid retention, Swelling, Erythema, Off label use, Off label use, |
||||
PRABOTULINUM TOXIN TYPE A, |
||||
| 163 | 26556391 |
US |
28 | |
Swelling face, Off label use, |
||||
PRABOTULINUM TOXIN TYPE A, |
||||
| 164 | 26556392 |
US |
||
Drug effect less than expected, Off label use, |
||||
PRABOTULINUM TOXIN TYPE A, PRABOTULINUM TOXIN TYPE A, PRABOTULINUM TOXIN TYPE A, |
||||
| 165 | 26556410 |
US |
||
Eyelid ptosis, Off label use, |
||||
PRABOTULINUM TOXIN TYPE A, PRABOTULINUM TOXIN TYPE A, PRABOTULINUM TOXIN TYPE A, |
||||
| 166 | 26556411 |
US |
||
Eyelid ptosis, Off label use, |
||||
PRABOTULINUM TOXIN TYPE A, PRABOTULINUM TOXIN TYPE A, PRABOTULINUM TOXIN TYPE A, |
||||
| 167 | 26556412 |
US |
||
Facial nerve disorder, Off label use, |
||||
PRABOTULINUM TOXIN TYPE A, |
||||
| 168 | 26556414 |
US |
||
Patient dissatisfaction with treatment, Off label use, Off label use, |
||||
PRABOTULINUM TOXIN TYPE A, |
||||
| 169 | 26556417 |
US |
40 | |
Drug ineffective, Off label use, |
||||
PRABOTULINUM TOXIN TYPE A, |
||||
| 170 | 26556431 |
52 | 1 | |
Kaposi^s sarcoma, Kaposi^s sarcoma, Kaposi^s sarcoma, Off label use, |
||||
TACROLIMUS, TACROLIMUS OINTMENT 0.1%, TACROLIMUS EXTENDED-RELEASE CAPSULES, PREDNISONE, MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL HYDROCHLORIDE, METHYLPREDNISOLONE SODIUM SUCCINATE, |
||||
| 171 | 26556452 |
US |
39 | |
Drug ineffective, Off label use, |
||||
PRABOTULINUM TOXIN TYPE A, PRABOTULINUM TOXIN TYPE A, |
||||
| 172 | 26556456 |
US |
57 | |
Eye disorder, Off label use, |
||||
PRABOTULINUM TOXIN TYPE A, PRABOTULINUM TOXIN TYPE A, PRABOTULINUM TOXIN TYPE A, |
||||
| 173 | 26556462 |
CA |
44 | |
Pulmonary embolism, Back pain, Chest pain, Dyspnoea, Pyrexia, Off label use, |
||||
INFLIXIMAB, |
||||
| 174 | 26556473 |
US |
49 | |
Drug ineffective, Off label use, |
||||
PRABOTULINUM TOXIN TYPE A, PRABOTULINUM TOXIN TYPE A, ONABOTULINUMTOXINA, |
||||
| 175 | 26556479 |
US |
||
Skin wrinkling, Eye disorder, Skin wrinkling, Off label use, Swelling, Dry eye, |
||||
PRABOTULINUM TOXIN TYPE A, ONABOTULINUMTOXINA, |
||||
| 176 | 26556486 |
CA |
40 | 2 |
Abdominal distension, Adverse reaction, Back injury, Bursitis, Coeliac disease, Condition aggravated, Dyspepsia, Fall, Finger deformity, Folliculitis, Gait inability, Gastrointestinal disorder, Gastrooesophageal reflux disease, Grip strength decreased, Headache, Hepatitis, Hypoaesthesia, Injury, Insomnia, Intentional product use issue, Liver function test increased, Malaise, Mobility decreased, Muscular weakness, Musculoskeletal stiffness, Nail disorder, Neck pain, Off label use, Pain in extremity, Pneumonia, Product label confusion, Weight increased, Wheezing, Wound infection, |
||||
RITUXIMAB, RITUXIMAB, RITUXIMAB, RITUXIMAB, RITUXIMAB, |
||||
| 177 | 26556492 |
US |
||
Sinusitis, Patient dissatisfaction with treatment, Off label use, |
||||
PRABOTULINUM TOXIN TYPE A, |
||||
| 178 | 26556496 |
US |
45 | |
Drug ineffective, Off label use, |
||||
PRABOTULINUM TOXIN TYPE A, |
||||
| 179 | 26556497 |
US |
||
Drug effect less than expected, Off label use, |
||||
PRABOTULINUM TOXIN TYPE A, |
||||
| 180 | 26556499 |
US |
45 | |
Drug ineffective, Off label use, |
||||
PRABOTULINUM TOXIN TYPE A, |
||||
| 181 | 26556500 |
US |
||
Drug ineffective, Off label use, |
||||
PRABOTULINUM TOXIN TYPE A, |
||||
| 182 | 26556501 |
US |
||
Drug ineffective, Off label use, |
||||
PRABOTULINUM TOXIN TYPE A, |
||||
| 183 | 26556502 |
US |
||
Drug ineffective, Off label use, |
||||
PRABOTULINUM TOXIN TYPE A, |
||||
| 184 | 26556504 |
US |
58 | |
Drug effect less than expected, Off label use, |
||||
PRABOTULINUM TOXIN TYPE A, PRABOTULINUM TOXIN TYPE A, |
||||
| 185 | 26556505 |
US |
49 | |
Drug effect less than expected, Off label use, |
||||
PRABOTULINUM TOXIN TYPE A, PRABOTULINUM TOXIN TYPE A, |
||||
| 186 | 26556506 |
US |
50 | |
Drug effect less than expected, Off label use, |
||||
PRABOTULINUM TOXIN TYPE A, PRABOTULINUM TOXIN TYPE A, |
||||
| 187 | 26556521 |
US |
57 | |
Drug effect less than expected, Off label use, |
||||
PRABOTULINUM TOXIN TYPE A, PRABOTULINUM TOXIN TYPE A, |
||||
| 188 | 26556522 |
US |
59 | |
Drug ineffective, Off label use, |
||||
PRABOTULINUM TOXIN TYPE A, |
||||
| 189 | 26556523 |
US |
||
Contusion, Pain, Therapeutic product effect delayed, Off label use, |
||||
PRABOTULINUM TOXIN TYPE A, |
||||
| 190 | 26556524 |
US |
||
Drug ineffective, Off label use, |
||||
PRABOTULINUM TOXIN TYPE A, |
||||
| 191 | 26556526 |
US |
55 | |
Drug ineffective, Off label use, |
||||
PRABOTULINUM TOXIN TYPE A, PRABOTULINUM TOXIN TYPE A, |
||||
| 192 | 26556529 |
US |
45 | |
Drug effect less than expected, Off label use, |
||||
PRABOTULINUM TOXIN TYPE A, PRABOTULINUM TOXIN TYPE A, |
||||
| 193 | 26556530 |
US |
53 | |
Drug ineffective, Off label use, |
||||
PRABOTULINUM TOXIN TYPE A, |
||||
| 194 | 26556532 |
US |
||
Bronchospasm, Fatigue, Off label use, |
||||
BRENSOCATIB, AMIKACIN, AZITHROMYCIN, AZITHROMYCIN MONOHYDRATE, AZITHROMYCIN DIHYDRATE, ALBUTEROL SULFATE, ALBUTEROL, SODIUM CHLORIDE, SODIUM CHLORIDE TABLET, SODIUM CHLORIDE TABLETS, |
||||
| 195 | 26556541 |
CA |
45 | |
Condition aggravated, Vomiting, Fistula, Platelet count decreased, White blood cell count increased, Fatigue, Clostridium difficile infection, COVID-19, Nausea, Hypertension, Arthralgia, Paraesthesia, Complication associated with device, Therapeutic response shortened, Off label use, Off label use, Intentional product use issue, |
||||
INFLIXIMAB, INFLIXIMAB, INFLIXIMAB, INFLIXIMAB, INFLIXIMAB, INFLIXIMAB, INFLIXIMAB, INFLIXIMAB, INFLIXIMAB, INFLIXIMAB, INFLIXIMAB, INFLIXIMAB, INFLIXIMAB, INFLIXIMAB, INFLIXIMAB, INFLIXIMAB, INFLIXIMAB, INFLIXIMAB, INFLIXIMAB, INFLIXIMAB, INFLIXIMAB, INFLIXIMAB, INFLIXIMAB, INFLIXIMAB, INFLIXIMAB, INFLIXIMAB, INFLIXIMAB, INFLIXIMAB, INFLIXIMAB, INFLIXIMAB, INFLIXIMAB, INFLIXIMAB, INFLIXIMAB, INFLIXIMAB, INFLIXIMAB, INFLIXIMAB, INFLIXIMAB, INFLIXIMAB, INFLIXIMAB, INFLIXIMAB, INFLIXIMAB, INFLIXIMAB, INFLIXIMAB, INFLIXIMAB, INFLIXIMAB, INFLIXIMAB, INFLIXIMAB, INFLIXIMAB, INFLIXIMAB, INFLIXIMAB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, CIPROFLOXACIN, CIPROFLOXACIN HYDROCHLORIDE, CIPROFOLXACIN, CIPROFLOXACIN TABLETS, CIPROFLOXACIN, CIPROFLOXACIN HYDROCHLORIDE, CIPROFOLXACIN, CIPROFLOXACIN TABLETS, CIPROFLOXACIN, CIPROFLOXACIN HYDROCHLORIDE, CIPROFOLXACIN, CIPROFLOXACIN TABLETS, DIPHENHYDRAMINE, DIPHENHYDRAMINE HYDROCHLORIDE, DIPHENHYDRAMINE, DIPHENHYDRAMINE HYDROCHLORIDE, DIPHENHYDRAMINE, DIPHENHYDRAMINE HYDROCHLORIDE, METRONIDAZOLE, METRONIDAZOLE, METRONIDAZOLE, FOLIC ACID, HYDROCORTISONE, ANTIPRURITIC (ANTI-ITCH), ANTI-ITCH CREAM, HYDROCORTISONE CREAM, HYDROCORTISONE 1%, HYDROCORTISONE CREAM 1%, ANTI-PRURITIC, HYDROCORTISONE CONTINUOUS SPRAY, HYDROCORTISONE LOTION, HYDROCORTISONE ACETATE, ANTI ITCH, ANTI-ITCH, COOL RELIEF GEL WITH ALOE, HYDROCORTISONE SPRAY, DRS. HYDROCORTISONE, HYDROCORTISONE, ANTIPRURITIC (ANTI-ITCH), ANTI-ITCH CREAM, HYDROCORTISONE CREAM, HYDROCORTISONE 1%, HYDROCORTISONE CREAM 1%, ANTI-PRURITIC, HYDROCORTISONE CONTINUOUS SPRAY, HYDROCORTISONE LOTION, HYDROCORTISONE ACETATE, ANTI ITCH, ANTI-ITCH, COOL RELIEF GEL WITH ALOE, HYDROCORTISONE SPRAY, DRS. HYDROCORTISONE, HYDROCORTISONE, ANTIPRURITIC (ANTI-ITCH), ANTI-ITCH CREAM, HYDROCORTISONE CREAM, HYDROCORTISONE 1%, HYDROCORTISONE CREAM 1%, ANTI-PRURITIC, HYDROCORTISONE CONTINUOUS SPRAY, HYDROCORTISONE LOTION, HYDROCORTISONE ACETATE, ANTI ITCH, ANTI-ITCH, COOL RELIEF GEL WITH ALOE, HYDROCORTISONE SPRAY, DRS. HYDROCORTISONE, HYDROCORTISONE, ANTIPRURITIC (ANTI-ITCH), ANTI-ITCH CREAM, HYDROCORTISONE CREAM, HYDROCORTISONE 1%, HYDROCORTISONE CREAM 1%, ANTI-PRURITIC, HYDROCORTISONE CONTINUOUS SPRAY, HYDROCORTISONE LOTION, HYDROCORTISONE ACETATE, ANTI ITCH, ANTI-ITCH, COOL RELIEF GEL WITH ALOE, HYDROCORTISONE SPRAY, DRS. HYDROCORTISONE, HYDROCORTISONE, ANTIPRURITIC (ANTI-ITCH), ANTI-ITCH CREAM, HYDROCORTISONE CREAM, HYDROCORTISONE 1%, HYDROCORTISONE CREAM 1%, ANTI-PRURITIC, HYDROCORTISONE CONTINUOUS SPRAY, HYDROCORTISONE LOTION, HYDROCORTISONE ACETATE, ANTI ITCH, ANTI-ITCH, COOL RELIEF GEL WITH ALOE, HYDROCORTISONE SPRAY, DRS. HYDROCORTISONE, HYDROCORTISONE, ANTIPRURITIC (ANTI-ITCH), ANTI-ITCH CREAM, HYDROCORTISONE CREAM, HYDROCORTISONE 1%, HYDROCORTISONE CREAM 1%, ANTI-PRURITIC, HYDROCORTISONE CONTINUOUS SPRAY, HYDROCORTISONE LOTION, HYDROCORTISONE ACETATE, ANTI ITCH, ANTI-ITCH, COOL RELIEF GEL WITH ALOE, HYDROCORTISONE SPRAY, DRS. HYDROCORTISONE, HYDROCORTISONE, ANTIPRURITIC (ANTI-ITCH), ANTI-ITCH CREAM, HYDROCORTISONE CREAM, HYDROCORTISONE 1%, HYDROCORTISONE CREAM 1%, ANTI-PRURITIC, HYDROCORTISONE CONTINUOUS SPRAY, HYDROCORTISONE LOTION, HYDROCORTISONE ACETATE, ANTI ITCH, ANTI-ITCH, COOL RELIEF GEL WITH ALOE, HYDROCORTISONE SPRAY, DRS. HYDROCORTISONE, METHOTREXATE, METHOTREXATE SODIUM, |
||||
| 196 | 26556555 |
US |
56 | |
Patient dissatisfaction with treatment, Off label use, Off label use, |
||||
PRABOTULINUM TOXIN TYPE A, PRABOTULINUM TOXIN TYPE A, |
||||
| 197 | 26556557 |
US |
40 | |
Drug ineffective, Off label use, |
||||
PRABOTULINUM TOXIN TYPE A, |
||||
| 198 | 26556562 |
US |
66 | |
Drug ineffective, Off label use, |
||||
PRABOTULINUM TOXIN TYPE A, |
||||
| 199 | 26556563 |
US |
37 | |
Drug ineffective, Off label use, |
||||
PRABOTULINUM TOXIN TYPE A, |
||||
| 200 | 26556564 |
US |
||
Patient dissatisfaction with treatment, Off label use, |
||||
PRABOTULINUM TOXIN TYPE A, |
||||
disclaimer
Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.
terms
license
last_updated
2026-04-28